Freedom-to-operate for GLP-1 receptor agonists and peptide therapeutics is among the most demanding FTO problems in pharmaceuticals, because protection in this class is built as a dense, layered thicket that extends far beyond the active ingredient. Freedom-to-operate determines whether making, using, or selling a product would infringe another party's active patent claims. In the GLP-1 and peptide space, answering that question requires reading many claim types across many patents, because a single product is protected by a stack of filings covering the molecule, its formulation, its dosing, its delivery device, and its manufacture. A peer-reviewed analysis of GLP-1 receptor agonists approved between 2005 and 2021 found that manufacturers listed a median of 19.5 patents per product, that 54 percent of those patents were on delivery devices rather than the active ingredient, that the median expected protection was 18.3 years after approval, and that no generic manufacturer had yet successfully challenged a GLP-1 receptor agonist patent.¹

The commercial stakes are large. Industry analyst forecasts vary widely with scope, placing the GLP-1 market anywhere from the low tens of billions of dollars to well over one hundred billion by 2030 and projecting double-digit annual growth; these are analyst estimates rather than authoritative figures, and they differ mainly in what they count.² The scale of the opportunity is what drives the density of the patent thicket, because each additional protected feature can delay competition on a high-revenue product. For any organization developing a follow-on peptide, a biosimilar, or a differentiated GLP-1 product, FTO is therefore a gating analysis rather than a formality.

Peptide therapeutics compound the difficulty. Peptides can be claimed as sequences and modifications, formulated for stability and half-life extension, delivered by injection or increasingly by oral routes, and manufactured through distinct synthesis and purification processes, so the claim surface is broad. Recent filing activity has shifted toward oral delivery, dual and triple receptor agonists, and combination therapies, which is where both the newest FTO risk and the remaining white space now sit.³ An FTO analysis in this class has to cover all of these dimensions, and it has to stay current as the frontier moves.

What creates FTO risk in GLP-1 and peptide products

Composition-of-matter claims. These cover the peptide itself, including sequences, analogues, and modifications, and are the primary protection, though in a mature class many core molecules approach expiry.

Formulation claims. These cover stabilized, extended-release, and oral formulations, which are heavily patented, as formulation is where much peptide innovation and differentiation occurs.

Dosing-regimen and method-of-use claims. These cover titration schedules and specific therapeutic uses, and can block a product for a particular indication or regimen even when the molecule is otherwise available.

Delivery-device claims. These cover injection pens and other devices and are a large share of the thicket; peer-reviewed analysis found delivery devices accounted for the majority of listed GLP-1 patents and function as a distinct barrier to entry.¹,⁴

Process and manufacturing claims. These cover synthesis and purification routes, so a developer can be free to use a molecule yet blocked from a particular manufacturing method.

A single molecule illustrates the layering. A published patent landscape of one dual GLP-1/glucagon receptor agonist identified twelve patent families spanning composition-of-matter, process chemistry, formulation, dosing regimen, and method-of-use, a clean worked example of how all five claim types stack on one product.⁵

The thicket dynamic and the expiry landscape

The density of GLP-1 protection reflects a broader pharmaceutical pattern. Empirical analysis shows the number of patents filed per active ingredient rose from 1.86 in 2001 to nearly six by 2019, driven substantially by continuation applications, which account for roughly a third of small-molecule pharmaceutical patents.⁶ These secondary filings extend the effective protection period, and the economics of that extension, including how patent challenges and settlements shape effective market life, are well documented.⁷ Pharmaceutical thickets also differ structurally from thickets in complex-technology industries, which is why FTO methods developed for electronics do not transfer cleanly to peptides.⁸

The expiry landscape is the other half of the picture. As core molecules approach the end of composition-of-matter protection, the surrounding formulation, device, and process claims determine when and where competition can actually enter. Analysis of one leading GLP-1 molecule found that the timing of primary-patent expiry varies substantially by market, so freedom-to-operate for a follow-on product is jurisdiction-specific, and the practical entry date is governed by the secondary thicket rather than the headline molecule expiry.⁹ For a developer, this means FTO must be assessed claim-by-claim and market-by-market, not at the level of the molecule.

How AI-powered FTO helps

Navigating a thicket of this density by manual search is slow and prone to coverage gaps, which are the main source of FTO risk. AI-powered FTO addresses this with semantic search that retrieves relevant claims regardless of terminology, claim-level analysis that focuses on the independent claims defining infringement scope across all five claim types, and continuous monitoring that keeps a cleared position current as new formulation, device, and combination filings publish. Because peptide innovation appears in scientific literature before it is patented, reading both patents and literature gives earlier warning of where the thicket is extending.

Where Cypris fits

Cypris runs claim-level, semantic, AI-powered freedom-to-operate across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology, across composition, formulation, dosing-regimen, delivery-device, and process claims, which is what a dense peptide thicket demands. The ontology clusters the thicket by concept and normalizes assignees, so a team sees the structure of protection around a molecule rather than a flat list. Cypris Q, the platform's agentic layer, lets teams run and chain FTO analysis conversationally, and Agentic Monitoring tracks a molecule and its surrounding thicket over time, flagging new formulation, device, and combination filings as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is freedom-to-operate hard for GLP-1 and peptide therapeutics?

Freedom-to-operate is hard for GLP-1 and peptide therapeutics because protection is built as a dense, layered thicket extending well beyond the active ingredient. A peer-reviewed analysis found GLP-1 products carry a median of 19.5 listed patents each, most of them on delivery devices. Assessing FTO requires reading composition, formulation, dosing, device, and process claims across many patents and markets.

What claim types create FTO risk for GLP-1 products?

Five claim types create FTO risk for GLP-1 products: composition-of-matter claims on the peptide, formulation claims on stabilized and oral forms, dosing-regimen and method-of-use claims, delivery-device claims, and process or manufacturing claims. Each can independently block a product. Delivery-device claims are a particularly large share of the GLP-1 thicket.

How many patents protect a typical GLP-1 product?

A peer-reviewed analysis of GLP-1 receptor agonists approved between 2005 and 2021 found a median of 19.5 listed patents per product, with 54 percent on delivery devices rather than the active ingredient, and a median of 18.3 years of expected protection after approval. No generic manufacturer had successfully challenged a GLP-1 receptor agonist patent as of that analysis. These figures illustrate the density of the thicket.

What is a pharmaceutical patent thicket?

A pharmaceutical patent thicket is a dense set of overlapping patents around a single product that extends protection beyond the core molecule. Empirical analysis shows patents per active ingredient rose from 1.86 in 2001 to nearly six by 2019, driven substantially by continuation applications. Thickets shape when and where competition can enter.

How does the expiry of GLP-1 patents affect freedom-to-operate?

The expiry of GLP-1 patents affects freedom-to-operate market-by-market, because primary-patent expiry timing varies by jurisdiction and the practical entry date is governed by the surrounding formulation, device, and process claims rather than the molecule alone. FTO must therefore be assessed claim-by-claim and market-by-market. A molecule can be off-patent in one country and still protected in another.

Where is the white space in GLP-1 and peptide development?

Recent filing activity has shifted toward oral delivery, dual and triple receptor agonists, and combination therapies, which is where both new FTO risk and remaining white space now sit. Mapping this frontier requires reading patents and scientific literature together, since peptide innovation appears in research first. White space analysis identifies the areas that are still open.

How does AI-powered FTO help with peptide therapeutics?

AI-powered FTO helps with peptide therapeutics by using semantic search to retrieve relevant claims regardless of terminology, claim-level analysis to focus on the independent claims that define infringement across all claim types, and continuous monitoring to keep a cleared position current. This is what a dense, fast-moving thicket requires. Cypris runs this across more than 500 million patents and scientific papers.

Which teams need GLP-1 and peptide FTO analysis?

GLP-1 and peptide FTO analysis is needed by pharmaceutical and biotech R&D, IP, and business-development teams developing follow-on peptides, biosimilars, differentiated formulations, or combination products. It is also relevant to generics manufacturers assessing entry. Cypris serves hundreds of enterprise customers across pharmaceuticals and other regulated industries.

How current does GLP-1 FTO need to be?

GLP-1 FTO needs to be continuously current, because new formulation, device, dosing, and combination filings publish constantly and can change a cleared position. A one-time assessment reflects only the moment it was run. Cypris uses Agentic Monitoring to track a molecule and its surrounding thicket over time and flag new filings as they publish.

Endnotes

1. Tu, S. S., Feldman, W. B., Alhiary, R., Gabriele, S., Kesselheim, A. S. & Beall, R. F. (2023). Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists. JAMA. https://doi.org/10.1001/jama.2023.13872
2. Industry analyst estimates (e.g., Research and Markets; BCC Research). GLP-1 market forecasts vary widely by scope and are presented here as order-of-magnitude estimates, not authoritative figures.
3. Han, J., Zhou, Z., Jiang, N. & Lu, W. (2023). An updated patent review of GLP-1 receptor agonists (2020–present). Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2023.2274905
4. Tu, S. S., Feldman, W. B. et al. (2024). Delivery Device Patents on GLP-1 Receptor Agonists. JAMA. https://doi.org/10.1001/jama.2024.0919
5. Fasi, M. A. (2026). Patent landscape and therapeutic evolution of mazdutide. Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2026.2645812
6. Tu, S. S. (2024). The Long CON: An Empirical Analysis of Pharmaceutical Patent Thickets. University of Pittsburgh Law Review. https://doi.org/10.5195/lawreview.2024.1049
7. Hemphill, C. S. & Sampat, B. N. (2012). Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics. https://doi.org/10.1016/j.jhealeco.2012.01.004
8. Tu, S. S. & Carrier, M. A. (2023). Why Pharmaceutical Patent Thickets Are Unique. SSRN. https://doi.org/10.2139/ssrn.4571486
9. Ramesh, S., Cross, S., Levi, J., Hill, A. & Venter, F. (2026). How Low Could Semaglutide Prices Fall? Implications for Global Access Ahead of Patent Expiry. Obesity. https://doi.org/10.1002/oby.70241

‍

Perovskite-silicon tandem solar cells have become the clearest path to a real jump in solar-panel efficiency in decades, and their patent landscape is distinctive because the underlying physics gives every developer the same target while leaving wide latitude in how to reach it. A single-junction silicon cell is capped by a physical ceiling that combines the Shockley-Queisser detailed-balance limit with Auger recombination losses; a Fraunhofer ISE analysis that combines both effects puts the accurate theoretical efficiency limit for a silicon-based monolithic tandem at 43.2 percent¹. The path to that ceiling runs through several distinct patenting layers. Interface passivation is currently the dominant lever on record efficiency: mixed self-assembled monolayer (SAM) contacts first enabled a certified 28.3 percent tandem², further interface-passivation work pushed a certified cell to 31.25 percent³, and subsequent bilayer SAM strategies have continued to close the non-radiative recombination gap⁴. A separate, equally central problem is depositing perovskite uniformly onto the pyramid-textured surface of industrial silicon wafers — the texture that gives production-grade silicon its light-trapping advantage also makes uniform, defect-free perovskite deposition difficult, typically causing localized electrical leakage at the pyramid peaks. Proposed fixes include selective passivation of the pyramid tips specifically (32.9 percent reported)⁵, "iceberg-like" pyramid engineering compatible with industrial texturing (33 percent)⁶, and advanced light-management approaches for textured interfaces more broadly⁷. Because record efficiency and manufacturable durability are driven by different, not always overlapping, sets of techniques, freedom-to-operate and white space analysis must span composition, interface, and texture-compatible process together.

The field has moved from a laboratory curiosity to early commercial shipment within the past two years, even as the record-chasing and the product-shipping efforts remain distinct. The current widely cited two-terminal cell efficiency record is 34.85 percent, announced by LONGi and stated by the company to be NREL-certified — a figure that should be read as certified-per-developer disclosure at cell area, since the independent certification certificate itself was not directly available in this research pass, and it is not (as of this writing) also a peer-reviewed published result⁸. This record is categorically distinct from module-level performance: Oxford PV and Fraunhofer ISE reported a full-size commercial-format module at 25 percent efficiency, a genuinely different, lower, and non-comparable figure because module-area results inherently lag cell-area records⁹. Preserving this cell-versus-module distinction, and the related single-junction-perovskite-versus-tandem distinction, matters throughout any reading of the field's efficiency claims. Commercial shipment and pilot-line status is confirmed via primary company disclosure for Oxford PV⁹; comparable primary shipment-volume disclosures for other major developers were not located in this pass and should be treated as unconfirmed pending each company's own investor-relations or regulatory filing. Because applications publish about eighteen months after filing, the most recent passivation and encapsulation filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

The strategic picture turns on which side of the record-versus-durability divide an owner is defending. Efficiency-record IP, concentrated in interface-passivation chemistry, is advancing quickly through a small number of well-resourced developers and research groups, and durability improvements are increasingly bundled with efficiency claims rather than reported separately in the most recent literature. The more open, commercially decisive ground remains the manufacturing and durability layer: deposition techniques compatible with textured industrial silicon at scale, and encapsulation and barrier-layer chemistry that closes the stability gap with silicon's multi-decade outdoor lifetime. Reading the landscape by layer, technique, and owner, and tracking both the patents and the underlying materials-science research, is what separates a workable manufacturing position from a blocked one.

Where the perovskite-silicon tandem white space is

Textured-silicon-compatible deposition. Depositing a uniform, leakage-free perovskite layer onto the pyramid-textured surface of industrial silicon wafers, rather than the flat substrates used for the highest record cells, is the central manufacturing barrier standing between lab records and mass production, with several distinct proposed solutions still competing⁵,⁶,⁷.

Encapsulation and durability chemistry bundled with efficiency. The most recent passivation literature increasingly targets stability and efficiency together rather than treating them as separate problems, which is itself a signal of where the field is converging.

Verified, primary-sourced commercial shipment data. Commercial shipment status is confirmed for Oxford PV via primary disclosure; comparable confirmation for other major developers remains outstanding, making rigorously verified shipment and production-volume claims a genuine differentiator.

Module-scale (not just cell-scale) efficiency. Because record efficiency is consistently reported at small cell area while commercial products are judged at full module scale, IP and technique that closes this cell-to-module gap is disproportionately valuable relative to further small-area record chasing.

Flexible and building-integrated form factors. Solution-processable, flexible tandem cells for curved surfaces, windows, and other building-integrated applications exploit perovskite's inherent advantages rather than competing directly with rigid silicon, and remain a less-crowded adjacent frontier.

How AI-powered landscape and white space analysis helps

Resolving a landscape that spans perovskite composition, interface chemistry, texture-compatible deposition, and encapsulation — where record-setting efficiency claims are announced by multiple developers within the same quarter, and where cell-area, module-area, certified, and company-announced figures are easily conflated — requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by layer and technique across varied terminology, attribution that normalizes solar-manufacturer, materials-supplier, and research-institution filers to canonical entities, and continuous monitoring that keeps pace with a field where the efficiency record itself changes multiple times a year. Because photovoltaics advances appear in materials-science literature before they are patented, reading both patents and literature gives the earliest signal of which technique is actually closing the gap between record cell and bankable product.

The competitive landscape by the numbers

The perovskite/tandem solar-cell patent family set totals roughly 12,575 documents, though this figure includes broader "tandem solar cell" and general photovoltaics art and therefore overstates perovskite-silicon-specific filings on its own (Cypris corpus, indicative; 2025–26 partial). Geography is led by China (approximately 1,994 families) and the United States (approximately 1,623), followed by Germany (approximately 846), Japan (approximately 773), and South Korea (approximately 758) (Cypris corpus, indicative; 2025–26 partial). Top assignees mix photovoltaics incumbents and materials firms — Trina Solar, Oxford Photovoltaics, Kaneka, LG, BASF, CEA, and JinkoSolar — alongside broader electronics players such as Canon and Toshiba, whose filings contribute some non-perovskite tandem/PV art to the set (Cypris corpus, indicative; 2025–26 partial). Filings show a recent perovskite-driven resurgence, rising from roughly 526 families in 2021 to about 1,191 in 2025 (Cypris corpus, indicative; 2025–26 partial).

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-moving materials fields such as perovskite-silicon tandem photovoltaics across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by layer, perovskite composition, interface passivation, tandem architecture, and encapsulation, and normalizes solar-manufacturer, materials-supplier, and research-institution filers to canonical entities, so a team can resolve which layers and techniques are crowded and which remain open as white space. Semantic search across patents and scientific literature connects filings to the underlying materials-science research, which is where tandem-cell advances appear first, often well ahead of the patent record. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined layer over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

What is a perovskite-silicon tandem solar cell? A perovskite-silicon tandem solar cell stacks a perovskite top cell on top of a crystalline-silicon bottom cell so the combined device captures more of the solar spectrum than either material could alone, allowing it to exceed the theoretical ceiling that limits any single-junction silicon cell. That combined ceiling, accounting for both Shockley-Queisser and Auger effects, is calculated at 43.2 percent¹. The current company-reported, NREL-certified cell-area record stands at 34.85 percent⁸.

Why can't a single-junction silicon cell just be made more efficient instead? A single-junction silicon cell cannot exceed its combined Shockley-Queisser/Auger efficiency ceiling because that limit is set by the fundamental physics of extracting energy from a broad-spectrum light source using a single semiconductor bandgap, not by manufacturing quality¹. Continuing to refine single-junction silicon can approach that limit but never exceed it. Stacking a second, complementary-bandgap material is the only way to break through it.

What layers does the tandem patent landscape cover? The landscape covers perovskite composition and bandgap engineering, interface passivation chemistry, tandem cell architecture compatible with industrial silicon texturing, and encapsulation and stability engineering. Interface passivation is currently the dominant lever on record efficiency²,³,⁴, while texture-compatible deposition remains the central manufacturing barrier⁵,⁶,⁷. A bankable product depends on progress across all of these layers together.

Are perovskite-silicon tandem panels available to buy in 2026? Only in limited volume, and only confirmed for certain developers. Oxford PV has a confirmed primary disclosure of a full-size commercial-format module reaching 25 percent efficiency in partnership with Fraunhofer ISE⁹, but comparable shipment-volume confirmation for other major manufacturers was not available in current primary disclosures. The efficiency record (34.85 percent, cell-area) and the shipping product (25 percent, module-area) are currently very different numbers describing different things.

Where is the white space in perovskite-silicon tandem solar cells? The white space includes textured-silicon-compatible deposition, durability chemistry bundled with efficiency gains, verified commercial shipment data, closing the cell-to-module efficiency gap, and flexible or building-integrated form factors. Record-efficiency IP is advancing quickly through interface-passivation chemistry specifically. The manufacturing, durability, and module-scale layers are the more open and commercially decisive ground.

Why is depositing perovskite onto textured silicon so hard? Depositing perovskite onto textured silicon is hard because industrial silicon wafers use a pyramid-textured surface to trap light and boost efficiency, but that same texture makes it difficult to deposit a uniform, defect-free perovskite layer, often causing localized electrical leakage at the pyramid peaks. The highest record cells are typically demonstrated on flatter or smaller-area substrates that partially avoid this problem. Multiple distinct fixes are being pursued in parallel, including selective peak passivation and engineered pyramid geometry⁵,⁶.

Why does perovskite-silicon tandem analysis need scientific literature? Perovskite-silicon tandem analysis needs scientific literature because composition, passivation, and encapsulation advances appear in materials-science research before they are patented, and because distinguishing certified from company-announced figures, and cell-area from module-area results, requires reading the primary literature rather than press coverage. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams use perovskite-silicon tandem patent landscape analysis? Perovskite-silicon tandem patent landscape analysis is used by R&D, IP, and strategy teams at solar manufacturers and materials suppliers, as well as investors assessing the photovoltaics sector. Because record efficiency and commercial durability are driven by different techniques at different maturity levels, and because efficiency claims require careful certified-versus-announced and cell-versus-module verification, structured analysis is essential. Cypris serves hundreds of enterprise customers across advanced materials, energy, and other research-intensive industries.

Endnotes

1. Schubert MC, Glunz SW, Fell A, Bivour M, Messmer C. Elucidating the efficiency limit of silicon-based monolithic tandem cells through the combination of Auger and Shockley-Queisser limits. EES Solar. DOI: 10.1039/d5el00085h.
2. Kishimoto K, Uzu H, Yamamoto K, Yoshida W, Okamoto S. 28.3% efficient perovskite-silicon tandem solar cells with mixed self-assembled monolayers. Applied Physics Express. DOI: 10.35848/1882-0786/ac727b.
3. Artuk K, Sahli F, Jeangros Q, Boccard M, Tabean S. Interface passivation for 31.25%-efficient perovskite/silicon tandem solar cells. Science. DOI: 10.1126/science.adg0091.
4. Jia Y, Xu X, Li P, Li Z, Xiao C. Perovskite/silicon tandem solar cells with bilayer interface passivation. Nature. DOI: 10.1038/s41586-024-07997-7.
5. Ye JP, Yang X, Ying Z, Du H, Yang W. Selective passivation of pyramid peaks for 32.9%-efficient perovskite/silicon tandem solar cells. Matter. DOI: 10.1016/j.matt.2026.102824.
6. Wei J, Li R, Yu X, Hang P, Wu T. Iceberg-like pyramids in industrially textured silicon enabled 33% efficient perovskite-silicon tandem solar cells. Nature Communications. DOI: 10.1038/s41467-025-62389-3.
7. Stannowski B, Korte L, Jošt M, Al-Ashouri A, Lipovšek B. Textured interfaces in monolithic perovskite/silicon tandem solar cells: advanced light management for improved efficiency and energy yield. Energy & Environmental Science. DOI: 10.1039/c8ee02469c.
8. LONGi Green Energy. 34.85%! LONGi Breaks World Record for Crystalline Silicon-Perovskite Tandem Solar Cell Efficiency Again. Company press release, longi.com.
9. Oxford PV and Fraunhofer ISE. Oxford PV and Fraunhofer ISE Develop Full-sized Tandem PV Module with Record Efficiency of 25 Percent. Fraunhofer ISE press release, ise.fraunhofer.de.
10. Cypris platform corpus analysis, perovskite/tandem solar-cell patent families. Indicative figures; 2025–2026 partial.

‍

Commercial fusion energy has moved from a distant public-research goal to a well-funded private race, and its patent landscape is being staked out as companies compress decades of physics into engineering programs. Fusion fuses light nuclei to release energy, and its progress is measured by the fusion gain, or Q, and the triple product of density, temperature, and confinement time, the parameters that determine whether a device produces more energy than it consumes.³ It is pursued through several competing confinement approaches, each a distinct region of patenting: magnetic confinement, including tokamaks, spherical tokamaks such as Globus-M2, stellarators, mirrors, and field-reversed configurations; inertial confinement using lasers; and magneto-inertial hybrids, running on fuels such as deuterium-tritium, deuterium-deuterium, and proton-boron.⁵ The intellectual property divides across the enabling technologies these approaches share: the magnets that confine the plasma, especially high-temperature superconducting magnets; the systems that heat and control the plasma; the tritium breeding blankets that must produce fuel and capture energy; the first-wall and divertor materials that survive intense neutron flux; and, for inertial approaches, the targets and drivers, whose implosion physics is an active research area.¹,⁶ Because a viable plant depends on several of these layers, freedom-to-operate and white space analysis must span the confinement approaches and the enabling layers together.

The landscape is being reshaped by a technology shift and a funding boom. High-temperature superconducting magnets, which reach much stronger fields than conventional superconductors, allow far more compact and potentially cheaper machines: the SPARC device, for example, is designed around a high-field, compact tokamak concept, and the physics basis for such burning-plasma machines is now well documented.² The 2025 edition of the IAEA's World Fusion Outlook gave these magnets a special focus, reflecting their role across tokamaks, stellarators, and mirror concepts.⁹ Public milestones anchor the field: in December 2022 the US National Ignition Facility achieved fusion ignition, producing about 3.15 megajoules of fusion energy from about 2.05 megajoules of laser energy delivered to the target, a scientific, target-level energy gain rather than a net-grid gain, and later experiments repeated ignition.⁷ On the magnetic side, ITER's 2024 re-baseline set the start of research operations in 2034 and the start of deuterium-tritium operations in 2039, a four-year delay from the earlier reference, and changed the first-wall material from beryllium to tungsten.⁸ Public programs are also advancing the physics, as with China's HL-3 tokamak.⁴ The intellectual-property picture is therefore a mix, because much of the underlying plasma physics is in the public domain from decades of open research, while the proprietary value concentrates in the specific engineering that turns physics into a machine. That split is visible in the record: across the Cypris corpus of more than 500 million patents and scientific papers, the fusion set holds on the order of 11,694 families and grew from about 376 in 2020 to roughly 711 in 2024, with the most active assignees being public institutes and diversified industrials, led by the Hefei Institutes of Physical Science of the Chinese Academy of Sciences alongside Toshiba, Hitachi, and the Japan Atomic Energy Agency, and China ahead of the United States and the United Kingdom on geography; 2025 and 2026 counts are partial because of the publication lag.

The strategic question is which enabling layer to own, and the white space sits where engineering, not physics, is the barrier. High-temperature superconducting magnet design and the manufacturing of the superconducting tape and cable are a high-value layer where a compact-machine advantage is won.² Tritium breeding, producing more tritium than the plant consumes, has not been demonstrated at commercial scale and is a critical, comparatively open area, as are the first-wall and divertor materials that must withstand neutron damage over a plant's life. Plasma heating and control, increasingly aided by machine learning, and, for inertial approaches, target fabrication and drivers, are further contested layers.⁶ Private-venture pilot-plant dates and net-gain targets should be read as company projections rather than demonstrated results. Reading the landscape by approach, enabling layer, and owner, and tracking both the patents and the underlying fusion-science research, is what separates a crowded region from an open one.

Where the fusion white space is

High-temperature superconducting magnets. Magnet design and the manufacturing of superconducting tape and cable for compact, high-field machines are a high-value, capital-intensive layer.²

Tritium breeding blankets. Breeding more tritium than the plant consumes, and capturing the fusion energy, is unproven at commercial scale and a critical, comparatively open area.

First-wall and divertor materials. Materials such as tungsten that survive intense neutron flux over a plant's life, and the strategies to replace them, are a distinct, high-stakes engineering layer.⁸

Plasma heating and control. Systems that heat, shape, and stabilize the plasma, increasingly using machine learning, are an active and contested layer.

Inertial targets and drivers. For inertial-confinement approaches, target fabrication and driver technologies are a separate region of patenting.¹,⁶

How AI-powered landscape and white space analysis helps

Resolving a landscape that spans several confinement approaches and enabling layers, built on public physics but proprietary engineering, requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by approach and enabling layer across varied terminology, attribution that normalizes private, public, and academic filers to canonical entities, and continuous monitoring that keeps pace with a fast-funding field. Because fusion advances appear in scientific literature before they are patented, and because so much of the science is public while the engineering is proprietary, reading both patents and literature is essential to separate open physics from claimable engineering.

Where Cypris fits

Cypris runs patent landscape and white space analysis for engineering-intensive deep-tech fields such as commercial fusion energy across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by confinement approach, tokamak, stellarator, inertial, and others, and by enabling layer, magnets, heating and control, tritium breeding, materials, and targets, and normalizes private, public, and academic filers to canonical entities, so a team can resolve which approaches and layers are crowded and which remain open as white space. Semantic search across patents and scientific literature connects filings to the underlying fusion-science research, which is where advances appear first and where public physics must be separated from proprietary engineering. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined layer over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

What is the commercial fusion energy patent landscape? The commercial fusion energy patent landscape is the set of patents covering the technologies needed to build a fusion power plant. It spans confinement approaches, tokamaks, stellarators, inertial, and others, and enabling layers such as magnets, plasma heating and control, tritium breeding, first-wall materials, and inertial targets. Each is a distinct region of patenting.

Why are high-temperature superconducting magnets so important? High-temperature superconducting magnets are important because they reach much stronger magnetic fields than conventional superconductors, which allows far more compact and potentially cheaper fusion machines. They have become a central engineering and patenting focus across several confinement approaches, and the 2025 IAEA World Fusion Outlook gave them a special focus. Magnet design and superconducting-tape manufacturing are high-value layers.

Why is tritium breeding a key white space? Tritium breeding is a key white space because a deuterium-tritium plant must produce more tritium than it consumes to be self-sufficient, and this has not been demonstrated at commercial scale. The breeding blanket must also capture the fusion energy and survive neutron flux. That combination makes it a critical, comparatively open engineering layer.

What did the NIF ignition result actually show? The National Ignition Facility achieved fusion ignition in December 2022, producing about 3.15 megajoules of fusion energy from about 2.05 megajoules of laser energy delivered to the target. This is a scientific, target-level energy gain, not a net-grid gain, because the laser system draws far more energy from the grid than reaches the target. Later experiments repeated ignition.

How does public physics affect fusion IP? Public physics affects fusion IP because decades of open, publicly funded research placed much of the underlying plasma physics in the public domain, so the proprietary, patentable value concentrates in the specific engineering, magnets, blankets, materials, targets, and control systems, that turns physics into a working machine. Distinguishing public science from claimable engineering is central to fusion freedom-to-operate.

Where is the white space in fusion energy? The white space includes high-temperature superconducting magnets and their manufacturing, tritium breeding blankets, first-wall and divertor materials, plasma heating and control including machine-learning approaches, and inertial targets and drivers. The physics is largely public. The most open, high-value opportunities are in the engineering layers that remain unproven at commercial scale.

Why does fusion analysis need scientific literature? Fusion analysis needs scientific literature because so much of the field's knowledge is in public research, and new engineering advances appear in the literature before they are patented, so reading both is essential to separate open physics from claimable engineering. Analyzing patents alone gives a partial view. Cypris analyzes both across more than 500 million patents and scientific papers.

What software helps analyze the fusion energy patent landscape? Software for the fusion landscape should cluster activity by confinement approach and enabling layer, resolve private, public, and academic filers to canonical owners, search patents and scientific literature semantically, and monitor a fast-funding field continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.

Endnotes

1. Chapman, T. D., Ralph, J. E., Woodworth, B., et al. (2024). Present understanding of ignition and gain using indirect-drive inertial confinement fusion on the U.S. National Ignition Facility. Plasma Physics and Controlled Fusion, 67(1). https://doi.org/10.1088/1361-6587/ad994f
2. Creely, A. J., Rice, J. E., Sorbom, B. N., Hartwig, Z. S., et al. (2022). Overview of the SPARC physics basis toward burning-plasma regimes in high-field, compact tokamaks. Nuclear Fusion, 62(4). https://doi.org/10.1088/1741-4326/ac1654
3. Costley, A. E. (2016). On the fusion triple product and fusion power gain of tokamak pilot plants and reactors. Nuclear Fusion, 56(6). https://doi.org/10.1088/0029-5515/56/6/066003
4. Chen, W., & Zhong, W. (2025). Breakthrough in China's fusion energy: HL-3 tokamak achieves high ion temperature and fusion triple product. The Innovation, 6. https://doi.org/10.1016/j.xinn.2025.101167
5. Sakharov, N. V., et al. (2021). Tenfold increase in the fusion triple product in the spherical tokamak Globus-M2. Nuclear Fusion, 61(6). https://doi.org/10.1088/1741-4326/abe08c
6. Zhou, Y., Sadler, J. D., & Hurricane, O. A. (2024). Instabilities and mixing in inertial confinement fusion. Annual Review of Fluid Mechanics, 57. https://doi.org/10.1146/annurev-fluid-022824-110008
7. U.S. Department of Energy (2022, December 13). DOE National Laboratory makes history by achieving fusion ignition. https://www.energy.gov/articles/doe-national-laboratory-makes-history-achieving-fusion-ignition
8. ITER Organization (2024). New baseline to prioritize a robust start to exploitation. https://www.iter.org/node/20687/new-baseline-prioritize-robust-start-exploitation
9. International Atomic Energy Agency (2025). Fusion energy in 2025: six global trends to watch (World Fusion Outlook 2025). https://www.iaea.org/newscenter/news/fusion-energy-in-2025-six-global-trends-to-watch

‍